OneOncology continued to strengthen its position as a national leader in community-based cancer research, with physician investigators from partner practices making a powerful showing at the field’s most influential scientific meetings in 2025.
In partnership with OneR, investigators presented nearly 50 abstracts at the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) Annual Meetings. These studies spanned solid tumors and hematologic malignancies alike, reflecting the breadth, sophistication, and growing impact of research conducted in independent community practices.
At ASCO, OneR investigators presented 23 abstracts across a wide range of cancers. Two studies were selected as “Best of ASCO,” recognizing early results from a novel injectable therapy for high-risk follicular lymphoma and long-term outcomes from a targeted therapy for high-risk chronic lymphocytic leukemia.
OneR’s research momentum continued at ASH as OneR and practice partner investigators delivered 25 presentations focused on lymphoma, leukemia, and multiple myeloma. Findings highlighted the safe administration of bispecific antibodies in community settings, continued expansion of CAR-T and cellular therapies into more aggressive diseases and frail populations, and promising results from next-generation targeted therapies.
Collectively, the research reinforced the essential role community sites play in advancing innovation across the full clinical trial spectrum — from first-in-human studies to practice-informing real-world evidence. Together, these achievements reflect OneOncology’s commitment to ensuring that cutting-edge research is not limited to academic centers, but available to patients where they live. By empowering community physicians to lead complex clinical research, OneOncology is helping shape the future of cancer care — making it more innovative, more inclusive, and more accessible for patients nationwide.